Key facts
- This page summarizes Brian Daniels's Form 4 filing for Artiva Biotherapeutics, Inc. (ARTV).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 14 Sep 2026, 16:03.
Brian Daniels - 10 Sep 2026 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)
- Reporting relationship
- Director
- Issuer ticker
- ARTV
- Reported as of
- 10 Sep 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Sep 2026, 16:03:37 UTC
- Prior SEC filing
- 08 Sep 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Bush, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Brian Daniels filed Form 4 for Artiva Biotherapeutics, Inc. (ARTV) on 14 Sep 2026.
Change
- Previous filing in this sequence was filed on 08 Sep 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001428698
Primary reporting owner
DANIELS BRIAN
- Relationship
- Director
- Address
- C/O ARTIVA BIOTHERAPEUTICS, INC., 5505 MOREHOUSE DRIVE, SUITE 100, SAN DIEGO
- Signature
- /s/ Jennifer Bush, Attorney-in-Fact
- Signature date
- 14 Sep 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ARTV
transaction
Derivative
Director Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +16,250
- Change %
- Price
- $0.000000*
- Shares after
- 16,250
- Date
- 10 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 16,250
- Exercise price
- $10.42
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.